These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26935193)

  • 21. Identification and characterization of Dlc1 isoforms in the mouse and study of the biological function of a single gene trapped isoform.
    Sabbir MG; Wigle N; Loewen S; Gu Y; Buse C; Hicks GG; Mowat MR
    BMC Biol; 2010 Mar; 8():17. PubMed ID: 20199662
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Silencing of DLC1 upregulates PAI-1 expression and reduces migration in normal prostate cells.
    Shih YP; Takada Y; Lo SH
    Mol Cancer Res; 2012 Jan; 10(1):34-9. PubMed ID: 22064653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer.
    Sabbir MG; Prieditis H; Ravinsky E; Mowat MR
    PLoS One; 2012; 7(7):e40302. PubMed ID: 22792269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Asymmetric localization of DLC1 defines avian trunk neural crest polarity for directional delamination and migration.
    Liu JA; Rao Y; Cheung MPL; Hui MN; Wu MH; Chan LK; Ng IO; Niu B; Cheah KSE; Sharma R; Hodgson L; Cheung M
    Nat Commun; 2017 Oct; 8(1):1185. PubMed ID: 29084958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The
    Hu J; Li X; Guo X; Guo Q; Xiang C; Zhang Z; Xing Y; Xi T; Zheng L
    J Cell Sci; 2017 Oct; 130(19):3399-3413. PubMed ID: 28818997
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous loss of the DLC1 and PTEN tumor suppressors enhances breast cancer cell migration.
    Heering J; Erlmann P; Olayioye MA
    Exp Cell Res; 2009 Sep; 315(15):2505-14. PubMed ID: 19482022
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential regulation of the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell migration and transformation.
    Cao X; Voss C; Zhao B; Kaneko T; Li SS
    Proc Natl Acad Sci U S A; 2012 Jan; 109(5):1455-60. PubMed ID: 22307599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Curcumin inhibits LPA-induced invasion by attenuating RhoA/ROCK/MMPs pathway in MCF7 breast cancer cells.
    Sun K; Duan X; Cai H; Liu X; Yang Y; Li M; Zhang X; Wang J
    Clin Exp Med; 2016 Feb; 16(1):37-47. PubMed ID: 25596714
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deleted in liver cancer 2 (DLC2) suppresses cell transformation by means of inhibition of RhoA activity.
    Leung TH; Ching YP; Yam JW; Wong CM; Yau TO; Jin DY; Ng IO
    Proc Natl Acad Sci U S A; 2005 Oct; 102(42):15207-12. PubMed ID: 16217026
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis.
    Wang Y; Lei R; Zhuang X; Zhang N; Pan H; Li G; Hu J; Pan X; Tao Q; Fu D; Xiao J; Chin YE; Kang Y; Yang Q; Hu G
    J Clin Invest; 2014 Apr; 124(4):1646-59. PubMed ID: 24590291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nuclear-targeted deleted in liver cancer 1 (DLC1) is less efficient in exerting its tumor suppressive activity both in vitro and in vivo.
    Chan LK; Ko FC; Sze KM; Ng IO; Yam JW
    PLoS One; 2011; 6(9):e25547. PubMed ID: 21966542
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rho GTPase-activating protein deleted in liver cancer suppresses cell proliferation and invasion in hepatocellular carcinoma.
    Wong CM; Yam JW; Ching YP; Yau TO; Leung TH; Jin DY; Ng IO
    Cancer Res; 2005 Oct; 65(19):8861-8. PubMed ID: 16204057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GAP-independent functions of DLC1 in metastasis.
    Barras D; Widmann C
    Cancer Metastasis Rev; 2014 Mar; 33(1):87-100. PubMed ID: 24338004
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer-Associated Point Mutations in the
    Wang D; Qian X; Sanchez-Solana B; Tripathi BK; Durkin ME; Lowy DR
    Cancer Res; 2020 Sep; 80(17):3568-3579. PubMed ID: 32606003
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DLC1 activation requires lipid interaction through a polybasic region preceding the RhoGAP domain.
    Erlmann P; Schmid S; Horenkamp FA; Geyer M; Pomorski TG; Olayioye MA
    Mol Biol Cell; 2009 Oct; 20(20):4400-11. PubMed ID: 19710422
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
    Yang X; Popescu NC; Zimonjic DB
    Cancer Res; 2011 Apr; 71(8):2916-25. PubMed ID: 21372205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DLC1 negatively regulates angiogenesis in a paracrine fashion.
    Shih YP; Liao YC; Lin Y; Lo SH
    Cancer Res; 2010 Nov; 70(21):8270-5. PubMed ID: 20861185
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tumor suppressor activity of DLC1 requires the interaction of its START domain with Phosphatidylserine, PLCD1, and Caveolin-1.
    Sanchez-Solana B; Wang D; Qian X; Velayoudame P; Simanshu DK; Acharya JK; Lowy DR
    Mol Cancer; 2021 Nov; 20(1):141. PubMed ID: 34727930
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of deleted in liver cancer 1 tumor suppressor by protein-protein interactions and phosphorylation.
    Ko FC; Ping Yam JW
    Int J Cancer; 2014 Jul; 135(2):264-9. PubMed ID: 24114040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SH3 domain regulation of RhoGAP activity: Crosstalk between p120RasGAP and DLC1 RhoGAP.
    Chau JE; Vish KJ; Boggon TJ; Stiegler AL
    Nat Commun; 2022 Aug; 13(1):4788. PubMed ID: 35970859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.